^
    Back
    Association details:
    Biomarker:FGFR2 S252W
    Cancer:Endometrial Cancer
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

    Excerpt:
    ...Activating mutations are defined as the known FGFR2 hotspots at S252W, P253R, S373C, Y376C, C383R, N550K, N550H, K660E....
    Trial ID:
    NCT01888562
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Biol Ther
    Title:

    Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations

    Excerpt:
    AP24534 significantly inhibited the proliferation of endometrial cancer cells bearing activating FGFR2 mutations (N549K, K310R/N549K, S252W) and mainly induced G1/S cell cycle arrest leading to apoptosis.
    DOI:
    10.1080/15384047.2015.1108492